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Aminoglycosides are a class of antibiotics with a broad spectrum of antimicrobial activity.
Unfortunately, resistance in clinical isolates is pervasive, rendering many aminoglycosides
ineffective. The most widely disseminated means of resistance to this class of antibiotics
is inactivation of the drug by aminoglycoside-modifying enzymes (AMEs). There are two
principal strategies to overcoming the effects of AMEs. The first approach involves the
design of novel aminoglycosides that can evade modification. Although this strategy has
yielded a number of superior aminoglycoside variants, their efficacy cannot be sustained in
the long term. The second approach entails the development of molecules that interfere
with the mechanism of AMEs such that the activity of aminoglycosides is preserved.
Although such a molecule has yet to enter clinical development, the search for AME
inhibitors has been greatly facilitated by the wealth of structural information amassed
in recent years. In particular, aminoglycoside phosphotransferases or kinases (APHs)
have been studied extensively and crystal structures of a number of APHs with diverse
regiospecificity and substrate specificity have been elucidated. In this review, we present
a comprehensive overview of the available APH structures and recent progress in APH
inhibitor development, with a focus on the structure-guided strategies.
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INTRODUCTION
Antibiotics are fundamental to the development and practice
of modern medicine. They are among the most frequently pre-
scribed medication. They are used to treat infections but also
function as prophylactics to guard against them. Moreover, they
are massively used in the agriculture, serving as prophylactic
agents and growth promoters in animal husbandry and fish farm-
ing (Lipsitch et al., 2002). The introduction of penicillin and
streptomycin into clinical use in the 1940s marked the beginning
of the golden age of antibiotic discovery. The vast majority of
antibiotics in our repertoire were discovered in the following three
decades by systematic empiric screening of fermentation prod-
ucts or chemicals for growth inhibitors of bacteria (Silver, 2011).
The surge in the popularity of antibiotics led to the emergence of
resistant pathogens. However, the severity of the situation was not
recognized, as alternatives seemed to be perpetually available. As
the discovery of new classes of antibiotics dwindled, the plight of
antibiotic resistance regained its prominence. The emergence of
bacterial resistance to antibiotic is inevitable but the overuse and
inappropriate use of antibiotics accelerate the rate. Furthermore,
high population densities in urban centers and ease of global
travel facilitate the spread of resistant pathogens (Bruinsma et al.,
2003; Carlet et al., 2012). As the current demographic trends
toward longer lifespans and the concomitant rise in the rate of
chronic and age-related illnesses (World Economic Forum, 2013),
the post-antibiotic era is imminent. There is a desperate need for
effective antibiotics.
The problem of antibiotic resistance has been on the fore-
front of public health authorities such as the World Health
Organization. Its first comprehensive report on the topic was
released in 2001 (World Health Organization, 2001) and antibi-
otic resistance was the focus for the World Health Day in 2011.
Recently, the World Economic Forum listed antibiotic resistance
as one of its cases in the Global Risks Report of 2013 (World
Economic Forum, 2013). Furthermore, the Ontario Medical
Association released a report in March 2013 addressing the issue
(Ontario Medical Association, 2013). The plight of antibiotic
resistance is irrefutable and the toll is alarming. Currently, about
100,000 people die from hospital-acquired infections a year in
the United States (Spellberg et al., 2011). It has been estimated
that antibiotic-resistant infections will impart on the healthcare
system an annual cost of over $21 billion in the United States
(Spellberg et al., 2011) and over $104 million in Canada (Wilson
et al., 2010).
Resistance to carbapenem, a class of last-resort antibiotics
derived from β-lactam, is rising and the mortality rate of
infections caused by carbapenem-resistant enterobacteriaceae
(CRE) is almost 50% (Borer et al., 2009). While the extent
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of resistance can be curbed by the prudent use of antibi-
otics, there remains the need for effective drugs with new
mechanisms of action that are not susceptible to existing resis-
tance mechanisms to combat such pathogens as methicillin-
resistant Staphylococcus aureus (MRSA), vancomycin-resistant
Enterococcus (VRE), and CRE. With no candidates in the antibi-
otic development pipeline, alternative strategies must be devised,
such as enhancing the human immunological response with vac-
cines (Mishra et al., 2012) or the use of bacteriophages (Gilmore,
2012). However, the strategy that shows the most promise is
the development of adjuvants to be used in combination with
the existing antibiotics, either as a booster of antibiotic activity
(Marks et al., 2012) or as an inhibitor of a resistant mecha-
nism (Kalan and Wright, 2011). Inhibition of the mechanism
of resistance is especially amenable for those antibiotics, such
as aminoglycosides, that are rendered ineffective by enzymatic
inactivation.
AMINOGLYCOSIDES
The first aminoglycoside, streptomycin, was isolated in 1943 from
Streptomyces griseus by Albert Schatz and Selman A. Waksan
(Schatz et al., 1944). It was a seminal discovery in the history of
antibiotics since streptomycin was the first effective treatment for
tuberculosis as well as the first useful antibiotic derived from a
bacterial source. In the ensuing three decades, more aminoglyco-
sides from actinomycetes have been identified and a number of
semisynthetic variants have also been developed.
Aminoglycosides encompass a large group of aminocyclitol-
containing molecules that are structurally diverse, hydrophilic,
and polycationic. They can be categorized into three major groups
based on their structures (Figure 1). The first group, which
includes streptomycin, contains a streptamine nucleus. The sec-
ond group, which includes spectinomycin and hygromycin B,
contains either a streptamine or a 2-deoxystreptamine nucleus
and they have distinctive structures due to their fused ring sys-
tems. The third and largest group, which includes paromomycin
and gentamicin, contains a 2-deoxystreptamine nucleus with
amino sugar rings substituted at either positions 4 and 5 or posi-
tions 4 and 6. The 6-amino hexose ring linked to position 4 of the
2-deoxystreptamine is designated as the prime (′) or A ring and
the pentose or hexose ring linked to position 5 or 6 is labeled the
double prime (′′) or C ring; the central 2-deoxystreptamine ring
is sometimes referred to as the B ring.
Aminoglycosides target the 30S ribosomal subunit of the
bacteria and interfere with protein synthesis. The three classes
of aminoglycosides have different binding targets in the ribo-
some as well as mechanisms of action. Streptomycin binds
to the 16S rRNA near a ribosomal accuracy switch, stabiliz-
ing the A-site in the ram or an “error-prone” state (Carter
et al., 2000). The higher affinity for aminoacyl-tRNA in the
ram state makes the binding of non-cognate tRNA more favor-
able and impairs the proof-reading mechanism (Karimi and
Ehrenberg, 1994). Spectinomycin is unique among the amino-
glycosides in that it is a bacteriostatic agent. It has been shown
to inhibit the translocation of the peptidyl-tRNA from the A-
to P-site (Bilgin et al., 1990). Based on the location of its bind-
ing site in the 30S ribosomal subunit, it is postulated that
spectinomycin acts by sterically hindering the conformational
changes or movements necessary for translocation (Carter et al.,
2000). 2-deoxystreptamine aminoglycosides induce errors in pro-
tein translation by binding to the A-site of the 16S rRNA (Moazed
and Noller, 1987) and trigger conformational changes that
improves the stability of the binding of near-cognate aminoacyl-
tRNA to the decoding center (Carter et al., 2000; Pape et al., 2000).
As a result, the ribosome incorporates erroneous amino acid
residues, synthesizing defective proteins, and precipitating cell
death.
Aminoglycosides have been an important component in the
antibiotic armamentarium due to their low cost, efficacy against
both Gram-negative and some Gram-positive bacteria, their syn-
ergism with other antibiotics, as well as their pharmacokinetic
and pharmacodynamic properties. Furthermore, some amino-
glycosides have also been shown to be effective against proto-
zoa (Berman and Fleckenstein, 1991) and Neisseria gonorrhoeae
(Duncan et al., 1972). Aminoglycosides are usually used as the
treatment of serious infections, such as septicemia, peritonitis,
and skin infections associated with burns, caused by Gram-
negative bacteria (Gonzalez and Spencer, 1998; Prayle and Smyth,
2010). In particular, tobramycin, gentamicin, and amikacin are
effective treatments for chronic respiratory infections caused by
Pseudomonas aeruginosa that plague patients with cystic fibrosis
(CF) (Prayle and Smyth, 2010). Aminoglycosides are also able
to target Gram-positive infections, such as endocarditis, when
used in combination with a cell wall active antibiotic, e.g., β-
lactams (Graham, 2002). Although streptomycin is no longer a
part of the anti-tuberculosis treatment regime, kanamycin and
amikacin are indicated for the treatment of multi-drug resis-
tant tuberculosis (MDR-TB) (Caminero et al., 2010). Nowadays,
aminoglycosides are more commonly reserved for second-line
antibiotic therapy due to their resistance in pathogens and their
nephrotoxic and ototoxic effects (Lopez-Novoa et al., 2011; Matt
et al., 2012). Although the adverse side effects have been miti-
gated with the evolution of dosing schemes (Begg and Barclay,
1995), resistance to aminoglycosides continues to rise to alarming
levels.
MECHANISMS OF RESISTANCE TO AMINOGLYCOSIDES
DECREASED INTRACELLULAR CONCENTRATION
Although the precise mechanism by which aminoglycosides enter
the bacterial cell remains elusive, the working model of amino-
glycoside uptake consists of three steps. The first step is thought
to be the non-specific electrostatic interaction between the poly-
cationic aminoglycosides and the negatively charged portions
of the bacterial membrane. Subsequent steps are dependent on
the membrane potential (Bryan et al., 1979; Taber et al., 1987).
Hence anaerobes are intrinsically resistant to aminoglycosides
(Bryan et al., 1979; Poole, 2005). Reduced accumulation of
aminoglycoside can be a result of reduced uptake of the antibi-
otic due to alterations in the composition of the membrane
surface or defects in the plasma membrane potential; alterna-
tively, aminoglycosides can be purged from the bacterial cell
by active efflux. Although relatively few bacterial drug efflux
systems are capable of removing aminoglycosides due to the
antibiotic’s polycationic nature (Poole, 2005), active efflux is
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FIGURE 1 | Chemical structure of different classes of
aminoglycoside antibiotics. (A) 4,6-disubstituted aminoglycosides,
(B) 4,5-disubstituted aminoglycosides, (C) spectinomycin, an atypical
aminoglycoside. The 2-deoxystreptamine nucleus in (A) and (B) are
highlighted in red and the streptamine nucleus in (C) is
highlighted in blue.
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the most common mechanism of aminoglycoside resistance in
lung isolates of P. aeruginosa from CF patients (Poole, 2011).
Repeated use of aminoglycosides upregulates the production of
the chromosomally encoded multidrug efflux system MexXY-
OprM, leading to a pan-aminoglycoside resistant phenotype
(Poole, 2011; Morita et al., 2012).
TARGET MODIFICATION
Alterations to the aminoglycoside binding site in the ribosome
can be brought about by ribosome mutation or enzymatic mod-
ification by methyltransferases. The resulting alteration in the
ribosome or the addition of a methyl group precludes the binding
of the antibiotic to its target site. Soon after its clinical imple-
mentation as treatment of tuberculosis, resistance to streptomycin
began to appear (Iseman, 1994). Aminoglycoside resistance to
Mycobacterium tuberculosis is most often a consequence of muta-
tions in the rpsL gene encoding the ribosomal protein S12 or
in the rrs gene encoding the 16S rRNA. A dominant resistance
phenotype in mycobacteria derived from ribosome mutations
can be attributed to the presence of a single rrn operon in this
pathogen (Meier et al., 1994). For resistance to streptomycin, the
most frequent mutations are detected in the rpsL gene, substi-
tuting a lysine at codon 43 or 88 with an arginine and in the
rrs gene in regions around nucleotides 530 and 915. An altered
rpsL or rrs gene accounts for 80% of streptomycin resistance inM.
tuberculosis strains (Meier et al., 1994). Similarly, a A1400G point
mutation leads to an amikacin/kanamycin resistance phenotype
(Alangaden et al., 1998).
Ribosomal methylation is becoming a significant mechanism
of aminoglycoside resistance in pathogens due to the high level
of resistance they confer and rapid worldwide dissemination (Doi
and Arakawa, 2007; Hidalgo et al., 2013). Methyltransfeases are
inherent in aminoglycoside-producing actinomycetes but they
were reported in 2003 having been found in P. aeruginosa and
Klebsiella pneumoniae (Galimand et al., 2003; Yokoyama et al.,
2003). These 16S-RMTases can be classified into two groups
based on the site of modification. The N7-G1405 16S-RMTases
constitute the larger group, having seven members. The methy-
lation at G1405 in the decoding center confers resistance to
4,6-disubstituted 2-deoxystreptmaine aminoglycosides. To date,
only one member of N1-A1408 16S-RMTase has been iden-
tified. A methylated A1408 is able to prevent the binding of
all 2-deoxystreptamine aminoglycosides (Wachino and Arakawa,
2012).
ENZYMATIC MODIFICATION OF AMINOGLYCOSIDES
By far, themost commonmechanism of resistance to aminoglyco-
sides is the covalent modification of the drug by aminoglycoside-
modifying enzymes (AMEs). The addition of chemical groups
prevents the binding of the aminoglycoside to the ribosome,
thereby conferring resistance. Three classes of AMEs are known:
acyl-coenzyme A-dependent acetyltransferases (AAC), nucleo-
side triphosphate-dependent nucleotidyltransferases (ANT), and
nucleoside triphosphate-dependent phosphotransferases (APHs).
Well over 100 AMEs have been identified to date (Ramirez and
Tolmasky, 2010) and numerous members from each of the three
classes have been subjects of extensive enzymatic and structural
studies. The prevailing nomenclature system for these enzymes
consists of a three-letter abbreviation identifying the enzyme
activity, followed by the site of modification or regiospecificity in
parentheses; next, the substrate spectrum is denoted by a Roman
numeral and finally a lower case letter indicates the individual
genes which confer identical resistance phenotypes (Shaw et al.,
1993).
The success of aminoglycoside resistance via enzymatic modi-
fication of the antibiotic can be attributed to the ability of many
of these enzymes to act on a range of aminoglycoside substrates,
and the fact that most aminoglycosides can be inactivated by
more than one AME. Their rapid dissemination is facilitated
by their frequent occurrences within various mobile genetic ele-
ments, often alongside additional antibiotic-resistance factors.
Moreover, mutation, recombination, and merging of genes have
led to the formation of new enzyme variants with expanded sub-
strate ranges including antibiotics unrelated to aminoglycosides
(Robicsek et al., 2006). As a result, there are intense interests in
exploring strategies to circumvent the deleterious effects of AMEs.
In particular, the aminoglycoside phosphotransferase or kinase
(APH) class of enzymes is the best-studied among the AMEs due
to their broad substrate spectra, wide-ranging regiospecificity,
and in particular, their ability to yield high levels of resistance
(Vakulenko and Mobashery, 2003). The wealth of structural
and mechanistic information amassed for APHs has made this
family of enzymes a prototype for the development of novel
anti-resistance compounds.
AMINOGLYCOSIDE KINASE (APH)
APHs transfer the γ-phosphate of the nucleoside triphosphate
cosubstrate to a hydroxyl nucleophile on the aminoglycoside
substrate in the presence of magnesium ions (McKay et al.,
1994). Collectively, the APH family can inactivate streptomycin,
all disubstituted 2-deoxystreptamine aminoglycosides, as well
as the atypical aminoglycosides spectinomycin and hygromycin
(Table 1). It was thought that the canonical phosphate donor
for these enzymes was ATP but it is now recognized that several
aminoglycoside kinases use GTP instead of or in addition to ATP
(Shakya and Wright, 2010; Frase et al., 2012; Shi and Berghuis,
2012).
To date, over 40 crystal structures of 8 established or putative
APH enzymes have been analyzed, covering APH(3′)-IIa (Nurizzo
et al., 2003), APH(3′)-IIIa (Hon et al., 1997), APH(2′′)-IIa (Young
et al., 2009), APH(2′′)-IIIa (Smith et al., 2012), APH(2′′)-IVa
(Shi et al., 2011), APH(4)-Ia (Stogios et al., 2011), APH(9)-Ia
(Fong et al., 2010), and Rv3168 (Kim et al., 2011). Detailed
structural information of the clinically important bifunctional
enzyme AAC(6′)-Ie/APH(2′′)-Ia remains elusive, but a low reso-
lution SAXS model has given us some preliminary insight on the
overall structure of this enzyme (Caldwell and Berghuis, 2012).
In addition, crystal structures of APH(3′)-Ia and two putative
aminoglycoside kinases have been released by various structure
genomics centers and await further analysis (PDB accession num-
bers 2R78, 3CSV, 3DXP).
The collection of APH structures available demonstrates
the diverse characteristics of this family of enzymes. APH(2′′),
with five members, and APH(3′) with seven members, are
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Table 1 | Substrate profiles of APH enzymes.
APHs Substrate References
APH(2′′)-I (bifunctional enzyme) Kanamycin, gentamicin, tobramycin, dibekacin, sisomicin, netilmicin,
amikacin, isepamicin, neomycin, ribostamycin, paromomycin,
lividomycin, butirosin
Ferretti et al., 1986; Daigle et al., 1999;
Toth et al., 2009
APH(2′′)-II Kanamycin, gentamicin, tobramycin, dibekacin, sisomicin, netilimicin,
amikacin, isepamicin, arbekacin
Kao et al., 2000; Toth et al., 2007, 2009
APH(2′′)-III Kanamycin, gentamicin, tobramycin, dibekacin, sisomicin, netilimicin Chow et al., 1997; Badarau et al., 2008;
Toth et al., 2009
APH(2′′)-IV Kanamycin, gentamicin, tobramycin, dibekacin, sisomicin, netilmicin,
amikacin, isepamicin, arbekacin
Tsai et al., 1998; Toth et al., 2009
APH(3′)-I Kanamycin, gentamicin, neomycin, ribostamycin, paromomycin,
lividomycin
Matsuhashi et al., 1975; Oka et al., 1981;
Pansegrau et al., 1987; Lee et al., 1991;
Shaw et al., 1993
APH(3′)-II Kanamycin, gentamicin, neomycin, ribostamycin, paromomycin,
butirosin
Matsuhashi et al., 1975; Perlin and
Lerner, 1981; Beck et al., 1982; Okazaki
and Avison, 2007; Shaw et al., 1993
APH(3′)-III Kanamycin, gentamicin, amikacin, isepamicin, neomycin,
ribostamycin, paromomycin, lividomycin, butirosin
Lambert et al., 1985; Trieu-Cuot and
Courvalin, 1986
APH(3′)-IV Kanamycin, neomycin, ribostamycin, paromomycin, butirosin Herbert et al., 1983, 1986
APH(3′)-V Kanamycin, neomycin, ribostamycin, paramomycin Thompson and Gray, 1983; Hoshiko et al.,
1988; Salauze and Davies, 1991
APH(3′)-VI Kanamycin, gentamicin, amikacin, isepamicin, neomycin,
ribostamycin, praomomycin, butirosin
Lambert et al., 1988, 1990; Martin et al.,
1988
APH(3′)-VII Kanamycin, amikacin, neomycin Tenover and Elvrum, 1988
APH(9)-I Spectinomycin Lyutzkanova et al., 1997; Suter et al., 1997
APH(4)-I Hygromycin Gritz and Davies, 1983; Rao et al., 1983
APH(7′′)-I Hygromycin Pardo et al., 1985; Zalacain et al., 1986
APH(6)-I Streptomycin Distler et al., 1987; Shinkawa et al., 1987;
Vögtli and Hütter, 1987
APH(3′′)-I Streptomycin Heinzel et al., 1988; Ramon-Garcia et al.,
2006
the two largest subfamilies of APHs (Ramirez and Tolmasky,
2010). Members of these subfamilies target different arrays
of disubstituted 2-deoxystreptamine aminoglycosides and their
prevalence among clinical isolates makes their structural infor-
mation invaluable. APH(4) and APH(9) subfamilies each has
only two members with a single substrate specificity. They are
clinically less significant since neither enzyme is common in
clinical isolates and hygromycin B, the substrate of APH(4)
is used only in animals. Nonetheless, their crystal structures
have provided important insights into the basis of substrate
binding and specificity. The following sections summarize our
structural understanding of the substrate binding sites of APH
enzymes.
OVERALL STRUCTURE
Determination of the first crystal structure of an aminoglycoside
kinase enzyme, APH(3′)-IIIa, revealed a striking resemblance to
the catalytic subunit of eukaryotic protein kinases (ePKs) (Hon
et al., 1997). Elucidation of crystal structures of other members
of the APH family confirm that APHs belong to the ePK super-
family of enzymes (Hanks and Hunter, 1995) (Figure 2), which
also includes choline kinase and some lipid kinases (Scheeff and
Bourne, 2005).
APH enzymes can be considered to have two lobes
(Figure 2A): the N-terminal and the C-terminal, which are con-
nected by a hinge segment. The N-terminal lobe consists of a
5-stranded antiparallel β-sheet flanked by a short helix in the
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FIGURE 2 | Overall structure of APH. (A) Secondary structure elements of a
typical APH enzyme. The N-terminal lobe is colored tan, the hinge region is
colored red, the core and helical subdomains in the C-terminal lobe are
colored green and purple, respectively. (B) Cartoon representation of
APH(2′′ )-IIa with ADP and gentamicin C1a in stick representation. The
location of the active site is highlighted by a surface where the nucleoside
pocket is colored blue, the triphosphate pocket is colored yellow, the catalytic
pocket is in green, and the specificity pocket is in purple.
N-terminus and a second longer α-helix located between β-
strands 3 and 4. The C-terminal lobe is largely α-helical and
can be further divided into the “core” and “helical” subdomains.
The N-terminal lobe and the core subdomain are well con-
served among APHs and ePKs and together they are involved in
the binding of nucleoside triphosphate and catalysis. The helical
subdomain is in contrast more variable in its composition and
architecture and it provides the framework for aminoglycoside
binding and recognition.
ACTIVE SITE ARCHITECTURE
The structural elements involved in nucleotide binding and
aminoglycoside binding are largely conserved among all known
APHs, despite significant amino acid sequence divergence. Based
on the numerous substrate-bound structures now available,
we can deconstruct the active site into four distinct subsites
(Figure 2B): (1) the nucleoside pocket, (2) the triphosphate
pocket, (3) the catalytic pocket, and (4) the specificity pocket.
Structural elements paralleling those of ePKs are found in their
respective pockets. Key residues in each subsite are summa-
rized in Figure 3 and discussed in more details in the following
sections.
Nucleoside pocket
The nucleoside pocket is a cleft described by residues from
strands 1, 2, and 3 of the β-sheet in the N-terminal lobe,
two short β-strands and adjacent loop regions from the core
subdomain, and the N-terminal segment of the hinge region.
Consistent with the less polar character of the cofactor bound
in this pocket, van der Waals interactions play an important
role in stabilizing the nucleoside moiety, and the purine base
is often sandwiched between hydrophobic sidechains projecting
from opposite sides of the cleft [e.g., Tyr42 and Ile207 in APH(3′)-
IIIa, Figure 3]. Few hydrogen-bonding interactions are observed,
with those consistently found forming between the purine base
and residues of the hinge region in a pattern reminiscent of that
seen inWatson-Crick base pairing. Despite considerable sequence
disparity (Figure 4), the structure of the nucleoside pocket is
well conserved, partly because many interactions occur with
the backbone atoms, which is particularly evident in the hinge
region [Ser91 and Ala93 in APH(3′)-IIIa, Figure 3] Although
the hinge region is an extended loop, it is thought to be rel-
atively inflexible, and its exact conformation has been linked
to controlling the nucleotide selectivity of APH enzymes (Shi
and Berghuis, 2012). Indeed, it has been noted that the GTP-
binding template is present even in ATP-specific APHs, but in
these enzymes the hinge region assumes a conformation such
that its orientation is not conducive for GTP-binding (Smith
et al., 2012). Crystal structures of APHs with GTP analogs have
shown that the guanine moiety tends to be bound less deeply
in the cleft compared to adenine and stabilization by the hinge
is crucial to its binding (Figure 5). In addition, the identity
of a residue lining the interior of the cleft or the back pocket
[Met90 in APH(3′)-IIIa, known as the gatekeeper residue in ePKs,
Figure 3] plays a pivotal role in determining which nucleotide is
preferred.
Triphosphate pocket
The triphosphate pocket connects the nucleoside pocket with
the catalytic pocket and resembles an enclosed channel in most
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FIGURE 3 | Cartoon representation of APH(3′)-IIIa (1L8T) with ADP and
kanamycin A in stick representation. Residues important for substrate
binding are displayed in stick representation and colored based on location:
nucleoside pocket (blue), triphosphate pocket (yellow), catalytic pocket
(green), and specificity pocket (purple). Two magnesium ions important for
phosphate binding are shown as light green spheres.
APH enzymes. Despite the negative charges present on the phos-
phate groups, there are very few basic residues lining this pocket,
perhaps to mitigate any unfavorable electrostatic effects on the
adjacent catalytic pocket. Instead, either one or a pair of mag-
nesium ions are typically employed for the coordination of the
phosphate moieties to conserved residues of the enzyme [Asn195
and Asp208 in APH(3′)-IIIa, Figure 3]. Upon nucleotide binding,
a Lys residue interacts with the α- and β-phosphates and prop-
erly orients the triphosphate moiety for catalysis. This Lys residue
[Lys44 in APH(3′)-IIIa, Figure 3] forms part of the highly con-
served F/Y-x-K motif in both APHs and ePKs and interacts with
a Glu residue from helix α2 [Glu60 in APH(3′)-IIIa, Figure 3].
Interestingly, APH(2′′)-IIIa, APH(4)-Ia and the putative amino-
glycoside phosphotransferase Rv3168 from Mycobacterium tuber-
culosis do not have the F/Y-x-K motif and feature an Arg in
the corresponding position instead. The nucleotide-bound crys-
tal structures show that this residue is involved in an identical
role in phosphate binding (Kim et al., 2011; Smith et al., 2012).
An Arg in this position has occasionally been observed for ePKs.
For most APH enzymes, a loop between strands β1 and β2,
often referred to as the nucleotide-positioning loop, has been
shown to undergo a large-scale rearrangement to fold over the
bound cofactor (Burk et al., 2001). The nucleotide positioning
loop is analogous to the glycine-rich G-loop found near the
catalytic site of many ePKs and key residues in this loop, includ-
ing Met26 and Ser27 in APH(3′)-IIIa (Figure 3), have been
demonstrated to enhance phosphoryl transfer and contribute
to a largely dissociative catalytic mechanism (Thompson et al.,
2002).
Catalytic pocket
The catalytic subsite is situated at the interface between the
core subdomain, the helical subdomain, and for some APHs
also the N-terminal lobe. Residues forming this subsite have
evolved to stabilize the aminoglycoside substrate such that the
hydroxyl group intended for phosphorylation is positioned in
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FIGURE 4 | Structure-based multiple sequence alignment of seven APH
enzymes and Rv3168 (PDB codes: 1L8T, 1ND4, 3HAM, 3TDV, 3SG8,
3TYK, 3I0O, 3ATT). Secondary structural elements are shown above the
alignment with nomenclature corresponding to APH(2′′ ) enzymes. Residues
are color-coded based on location: nucleoside pocket (blue), triphosphate
pocket (yellow), catalytic pocket (green), and specificity pocket (purple). The
catalytic aspartate is highlighted in red. Conserved residues are indicated
with a star. Residues with a gray background were found in structurally
identical locations, and in cases where two subsets of enzymes have
different structurally conserved elements, a tan background was used in
addition to gray. Residues with a white background represent structural
elements or conformations specific to a single enzyme. Inserts are shown as
purple boxes, with the number displayed indicating the number of residues
inserted at that location.
FIGURE 5 | Nucleoside binding pockets of (A) APH(3′ )-IIIa (1L8T)
with ADP (cyan), (B) APH(2′′ )-IVa (4DT9) with guanosine (orange),
and (C) APH(9)-Ia (3I0Q) with AMP (green). The binding modes of
the nucleotide substrate and an ePK inhibitor [(A,C) CKI-7, (B)
quercetin] are compared. For each panel, the gatekeeper residue and
two hinge residues that form the ATP/GTP binding template are
highlighted in blue stick representation. Hydrogen-bonding interactions
between the hinge and the substrate are shown as black dotted
lines and those between the hinge and the inhibitor are shown as
gray dotted lines. The black arrows point to a hydrophobic back
pocket in each binding site that is not normally occupied by the
nucleotide substrate.
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close proximity to the catalytic loop containing an essential Asp
residue [Asp190 in APH(3′)-IIIa, Figure 3] as part of the con-
served H-x-D-x-x-x-x-N sequence, also known as the Brenner
motif (Brenner, 1987). Since the ring bearing the target hydroxyl
group differs among the APH subfamilies, the catalytic subsite is
correspondingly diverse. In APH(3′) enzymes, this pocket binds
the neamine core scaffold common to 4,5- and 4,6-disubstitued
aminoglycosides (rings A and B) (Fong and Berghuis, 2002),
whereas for the APH(2′′) subfamily, this pocket binds the double
prime ring or ring C in 4,6-disubstituted aminoglycosides (Young
et al., 2009).
Specificity pocket
The specificity pocket is located deeper in the divide between
the helical and core subdomains. In APH(4)-Ia, APH(2′′) and
APH(3′) enzymes this pocket is negatively charged, comple-
mentary to the cationic aminoglycoside substrates; whereas in
APH(9)-Ia, this pocket is predominantly neutral corresponding
to the non-polar nature of the spectinomycin substrate.
Although each subfamily of APH has a unique range of sub-
strates, structural elements in this subsite are largely conserved.
The binding of the aminoglycoside substrates are effected by
interactions with residues located on the C-terminal portion
of the catalytic loop, residues located on helix α4 in the core
subdomain, as well as those on helix αC in the helical sub-
domain. In APH(4)-Ia, APH(9)-Ia, and APH(2′′) enzymes, the
helical subdomain is composed of a relatively rigid four-helix
bundle. It has been observed in APH(2′′)-IVa and APH(9)-Ia
that these enzymes undergo a conformation change upon the
binding of the antibiotic that involves in part a small move-
ment in the helical subdomain. It has been hypothesized that
the limited flexibility of helices contribute to the formation of
more rigid binding pockets and thus smaller substrate ranges
for these subfamilies of APHs (Stogios et al., 2011). Indeed, for
APH(2′′) enzymes, favorable electrostatic interactions and a large
number of hydrogen-bonds ensure that rings A and B are sta-
bilized with very restricted conformational freedom (Shi et al.,
2011). This limits the selectivity of the APH(2′′) subfamily to
4,6-disubstituted aminoglycosides, because if 4,5-disubstituted
aminoglycosides were bound in a catalytically competent manner,
the neamine core scaffold would clash with the helical sub-
domain. Instead, the interactions of the specificity subsite are
sufficiently strong that it is likely that when 4,5-disubstituted
aminoglycosides bind to APH(2′′) enzymes, the interactions with
rings A and B would be maintained, thus causing ring C and the
target hydroxyl group to be oriented away from the catalytic loop,
which renders this class of aminoglycosides competitive inhibitors
rather than substrates (Toth et al., 2010). Similarly, the speci-
ficity subsite in APH(4)-Ia or APH(9)-Ia could be considered
so restrictive that only hygromycin B or spectinomycin, respec-
tively, are recognized as substrates (Fong et al., 2010; Stogios et al.,
2011). Notably, the C-terminal helix αD is significantly longer in
APH(4)-Ia and APH(9)-Ia, and its position as well as the orien-
tation of the helical subdomain as a whole give rise to a more
compact and defined specificity pocket relative to APH(2′′). In
addition to the gross secondary structural elements, in APH(4)-
Ia the single substrate specificity can also be attributed to the
presence of hydrophobic residues in the specificity pocket that
correspond to the unique twisted shape of hygromycin B; whereas
in APH(9)-Ia, the polar groups of spectinomycin are comple-
mented by localized polar areas in the neutrally charged specificity
pocket.
In contrast, the specificity subsite of the APH(3′) subfamily
contains distinct structural features that strongly influence the
aminoglycoside selectivity of the enzyme. The APH(3′) enzymes
are notable among the APHs due to their ability to phos-
phorylate both 4,5- and 4,6-disubstituted 2-deoxystretpamine
aminoglycosides (Shaw et al., 1993). The specificity subsite of
APH(3′) is comparatively spacious and can be seen as hav-
ing two parts, one for binding 4,5-disubstituted aminoglyco-
sides, and another for binding 4,6-disubstituted variants (Fong
and Berghuis, 2002). Furthermore, APH(3′) enzymes have a
reduced helical subdomain, containing only three helices (αA,
αB, and αC). Most remarkably, however, is the loop insertion
between αA and αB. The plasticity of the aminoglycoside bind-
ing site in APH(3′) enzymes can be partially ascribed to this
flexible region termed the aminoglycoside-binding loop. This
loop undergoes a conformation change upon the binding an
aminoglycoside and folds toward the substrate, thereby com-
pleting the binding pocket and allowing a number of acidic
residues in this loop to form hydrogen bonds with the sub-
strate (Glu157 and Glu160, Figure 3). While the interactions
between the substrates and residues on αC (Glu262 and Phe264,
Figure 3) are critical (Thompson et al., 1999), the flexible
aminoglycoside-binding loop makes it possible to customize the
size and shape of the specificity pocket, allowing the enzyme to
adapt to the structurally different substrates (Fong and Berghuis,
2009).
STRATEGIES TO COUNTERACT ENZYME-MEDIATED
RESISTANCE
Broadly, two strategies are considered in overcoming AME-
mediated resistance. The first involves the development of novel
antibiotic compounds that can evade inactivation by resistance
enzymes; the second requires inhibition of the resistance mech-
anism such that the activity of existing aminoglycosides can
be restored. Both of these approaches have precedents in the
β-lactam class of antibiotics. The semi-synthetic β-lactam methi-
cillin was the first antibiotic to successfully evade resistance by
degradative enzymes (Sheehan, 1967). Methicillin differs from
its parent compound in a side chain substitution on the 6-
aminopenicillic acid core, resulting in a significant reduction
in binding affinity to penicillinase enzymes and is therefore
able to retain its antibiotic activity. Alternatively, penicillinase
can be thwarted by β-lactamase inhibitors, which bind irre-
versibly to β-lactamase enzymes. Some have successfully been
co-formulated with β-lactam antibiotics for the treatment of
β-lactam-resistant infections (Drawz and Bonomo, 2010). For
aminoglycosides, clinical success has resulted from development
of aminoglycosides that evade resistance, similar to methicillin.
However, aminoglycoside adjuvants acting as AME inhibitors
have yet to progress to the clinic. The following sections summa-
rize the strategies under investigation to counteract the activities
of AMEs.
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EVADING RESISTANCE
Removal of modifiable groups
Removal of functional groups of aminoglycosides targeted by
AMEs has yielded some success in combating resistance. These
modified compounds are able to elude inactivation by specific
AMEs while retaining their ability to bind to the ribosome
and exert their bactericidal effects. The semisynthetic dibekacin
(3′,4′-dideoxykanamycin B) (Umezawa et al., 1971) was modeled
after the naturally occurring tobramycin (3′-deoxykanamycin B)
(Koch and Rhoades, 1970) to avoid AME-mediated modification.
Both compounds lack the 3′-hydroxyl group, and are therefore
useful against bacteria that harbor the aph(3′) resistance factor.
Nonetheless, they can still be modified by AMEs with different
regiospecificities. Furthermore, the feasibility of this strategy is
limited since many of the functional groups of aminoglycosides
are tightly linked to their antibacterial properties (Salian et al.,
2012).
Steric hinderance
Butirosin, the naturally occurring 4,5-disubstituted aminogly-
coside containing a (S)-4-amino-2-hydroxybutyrate (AHB) at
position 1 of the 2-deoxystreptamine (Figure 1B), is an effec-
tive aminoglycoside that is resistant to the action of many AMEs.
It is postulated that the bulky AHB interferes with binding
to the active site of many AMEs (Fong and Berghuis, 2009).
Consequently, an AHB group was added to kanamycin and
dibekacin to produce amikacin (Kawaguchi et al., 1972) and
arbekacin (Kondo et al., 1973), respectively (Figure 1A). While
the introduction of 3-amino-2-hydroxypropionate (AHP) to gen-
tamicin B produces isepamicin (Nagabhushan et al., 1978), the
addition of an ethyl group to sisomicin generates netilmicin
(Wright, 1976) (Figure 1A). These derivatives have been shown to
be clinically useful. Notably, arbekacin has been a success in Japan
for the treatment of MRSA infections (Kondo and Hotta, 1999)
as it lacks the modifiable hydroxyl groups at positions 3′ and 4′
and its antibiotic activity is unaffected by acetylation at the 2′- or
3′′-positions (Hotta et al., 1996, 1998). In addition to providing
protection against AMEs, the AHB group also contributes to the
binding to its target site in the ribosome. The crystal structure of
amikacin bound to the decoding center revealed that amikacin
binds the A-site in the same fashion as its parent compound
kanamycin, supplemented with favorable contacts formed by the
AHB (Kondo et al., 2006).
Analogous to the N1-acylated aminoglycosides, Shaul et al.
recently reported on the generation of 6′- and 6′′′-acylated
tobramycin and paromomycin (Shaul et al., 2011). Some deriva-
tives were able to exert antibiotic activity in the presence of some
AMEs. However, unlike the derivation at position N1 of the 2-
deoxystreptamine that has been successfully applied to a range of
aminoglycosides, only specific permutations of selective amino-
glycosides and acyl groups substituted at the 6′- or 6′′′-position
give rise to aminoglycoside derivatives that are active against
bacterial strains carrying various AMEs.
Capitalizing on the crystal structures of the ribosome in com-
plex with various aminoglycosides as well as the success of
aminoglycoside derivatives with an acyl substitution at position
1 of the 2-deoxystreptmaine ring and lacking selected modifiable
groups, two analogous novel aminoglycosides have been devel-
oped. Plazomicin (previously ACHN-490), a “neoglycoside,” rep-
resents the leading candidate for “next-generation” aminoglyco-
sides. It is derived from sisomicin, with the addition of an AHB
group at position 1 of the 2-deoxystreptamine and a hydroxyethyl
group at position 6′. These two modifications, combined with the
inherent lack of 3′- and 4′- hydroxyl groups in sisomicin com-
bine to produce an aminoglycoside that is resistant to all tested
aminoglycoside resistance enzymes with the exception of AAC(2′)
enzymes, a resistance factor that has not been observed in clini-
cal strains (Armstrong and Miller, 2010). In early 2012, Phase II
clinical trials have successfully been completed for the treatment
of complicated urinary tract infections and acute pyelonephritis,
without the nephrotoxicity or ototoxicity often associated with
aminoglycoside therapy (Cass et al., 2011). A related molecule
2′′-O-(phenethylamino)ethyl- and 1-N-AHB-substituted 3′,4′-
dideoxy paromomycin showed potent antibiotic activity against
a range of resistant bacteria including vancomcyin resistant S.
aureus (VRSA) and vancomycin intermediate S. aureus (VISA)
strains (Hanessian et al., 2010). Moreover, the crystal structure
of this variant paromomycin with an RNA fragment containing
the A-site revealed that it has an altered binding mode com-
pared to the parent paromomycin compound (Kondo et al.,
2007).
A new generation of aminoglycosides would promise a fea-
sible path in the mitigation of the effects of AMEs in resistant
bacteria. However, coevolution of AMEs will likely accompany
the introduction of novel aminoglycoside variants into the ther-
apeutic regime thus jeopardizing the longevity and effectiveness
of these new drugs. Such a phenomenon can be exemplified by a
variant of aminoglycoside acetyltransferase AAC(6′)-Ib in which
a change in two base pairs in its gene was sufficient to extend
the enzyme’s substrate specificity to include ciprofloxacin, a syn-
thetic antibiotic belonging to the fluoroquinolone class, resulting
in a decreased susceptibility to ciprofloxacin (Robicsek et al.,
2006).
CURRENT APPROACHES TO APH INHIBITOR DISCOVERY
Thus far, attempts at developing a potent and specific inhibitor
against APHs have not been successful. Given our growing under-
standing of the structure and mechanism of APHs, a strong
case can be made for structure-guided design of an inhibitor, an
approach that has not been explored for finding inhibitors for this
class of enzymes.
An ideal APH inhibitor would universally target most if not
all members of the APH family with high affinity and speci-
ficity such that little to no cross-reactivity with ePKs or other
human enzymes would occur. Although the prospect of such a
pan-APH inhibitor is poor, it is not unrealistic to aim for the
development of an inhibitor that can effectively target a selec-
tion of APHs such as members of the same subfamily. In general,
Figure 4 shows that residues forming the triphosphate pocket are
the most conserved among the APHs. However, accessibility of
this subsite is poor and the sequence conservation also extends to
ePKs, thus suggesting that while targeting this subsite may yield
an inhibitor capable of acting against multiple APHs, selectivity
toward resistance enzymes will be difficult to obtain. On the other
Frontiers in Cellular and Infection Microbiology www.frontiersin.org June 2013 | Volume 3 | Article 22 | 10
Shi et al. Circumventing aminoglycoside kinase mediated resistance
hand, the large variations in the aminoglycoside-binding site,
reflective of the diverse substrate-profiles and regiospecificity of
APHs (Table 1), leaves little opportunity for a common inhibitor,
thereby leaving the nucleoside pocket the most promising site
of inhibition. This subpocket has served as a starting point for
many structure-guided inhibitor design studies since this pocket
at once shows strong conservation among APHs and bears small
but significant differences with ePKs, which offer opportunities
for specificity.
Adapting ePK inhibitors
ePKs are of significant medical relevance due to their cen-
tral roles in signal transduction and regulatory pathways.
Deregulation or overexpression of ePKs plays a role to many
diseases, including diabetes and some cancers. As a conse-
quence, a plethora of ePK inhibitors have been developed, most
of which target the ATP-binding pocket. Soon after the struc-
tural homology between APHs and ePKs was uncovered, several
known inhibitors of ePKs were assayed for their activity toward
APHs. Isoquinolinesulfonamide derivatives, notably CKI-7 (1,
Figure 6), were among the first compounds discovered to inhibit
some APHs such as APH(3′)-IIIa (Daigle et al., 1997). Recently,
a more comprehensive screening for APH inhibitors was car-
ried out by Shakya et al., who tested a set of 14 aminoglycoside
and macrolide phosphotransferases against a library of 80 protein
kinase inhibitors with diverse chemical scaffolds (Shakya et al.,
2011). The resulting data allowed the authors to construct a small
molecule discrimination map of the most commonly encoun-
tered APH enzymes. It was discovered, for instance, that some
ePK inhibitors such as quercetin (2) or damnacanthal (3) were
active against multiple APHs, while some APHs, including the
clinically relevant APH(2′′)-Ia, was virtually unaffected by all
compounds tested. Interestingly, APH(2′′)-Ia was shown to be
inhibited by CKI-7 in the previous study (Daigle et al., 1997). A
natural next step would be to gain better understanding of the
specific mode of binding of the more promising leads identified
thus far and explore distinctive structural features in order to
modify the inhibitors for improved specificity. Recently, the crys-
tal structures of APH(3′)-IIIa and APH(9)-Ia in complex with
CKI-7 were determined, representing the first co-crystal struc-
tures of an APH with an active small molecule inhibitor (Fong
et al., 2011). More ePK inhibitor-bound structures of APH have
since been solved, including one of APH(2′′)-IVa bound with
the wide-spectrum flavonol type inhibitor, quercetin (2) (Shakya
et al., 2011), as well as a series of ePK inhibitor-bound struc-
tures APH(3′)-Ia solved by the Center for Structural Genomics of
Infectious Diseases (PDB accession numbers 4GKH, 4GKI, 4FEU,
4FEV, 4FEW, 4FEX).
Crystal structures of APH-CKI-7 complexes solved by Fong
et al. show that the inhibitor-bound enzyme conformation largely
parallels that of the ATP-bound state (Fong et al., 2011). A notable
difference is observed in the conformation of the region termed
the glycine-rich loop in ePKs [res. 21-27 in APH(3′)-IIIa], which
in the inhibitor-bound complex resembles more the apo APH
structures than the nucleotide-bound structures. The equiva-
lent region in APH(2′′)-IVa adopts the same conformation in
the apo, adenosine-bound, and the quercetin-bound structures
(Shakya et al., 2011; Shi et al., 2011; Shi and Berghuis, 2012). The
binding mode of the inhibitors are comparable to that of the ade-
nine ring, making van der Waals interactions with the non-polar
side chains and hydrogen bond interactions with the main chain
atoms in the hinge regions. Further analyses on the structure-
activity relationship between various ePK inhibitors and APHs
confirm the critical nature of these hydrogen bond interactions
(Sowadski et al., 1999; Fong et al., 2011; Shakya et al., 2011).
Comparative analysis with the crystal structure of CKI-7 bound
to the ePK casein kinase 1 revealed many similarities in the mode
of inhibitor binding. However, a number of subtle distinguish-
ing features in the nucleotide-binding site of APH enzymes, such
as the conformation of the hinge region and the presence of
a large aromatic residue capable of forming stacking interac-
tions with the isoquinoline portion of the inhibitor, can serve as
starting points for the development of APH-specific inhibitors.
Though many types of ATP-competitive inhibitors developed for
ePKs show activity against APHs, their inhibition constants are
invariably significantly higher, which by itself suggests that bind-
ing pockets of APHs are still sufficiently different from most
ePKs to allow for more specific targeting. This is corroborated by
the crystal structures of quercetin-bound APH(2′′)-IVa (Shakya
et al., 2011) and various ePKs (PDB accession numbers 1E8W,
2HCK, 2O3P, and 3LM5) in which the inhibitor binds to each
kinase in a unique manner as a result of the different interactions
effected by the non-conserved elements in the nucleoside-binding
pocket.
In a similar vein, some lipid kinases are known to share a com-
parable fold with ePKs and APHs, and the PI-3 kinase inhibitor
wortmannin (4) has been shown to inhibit APH(2′′)-Ia (Boehr
et al., 2001). A prominent concern of this translational approach
is of course the specificity of the inhibitor. As the APH-CKI-7
crystal structures demonstrate, the inhibitor’s mode of binding
closely resembles that seen for ePKs such as casein kinase 1. More
structural information will prove instrumental in the develop-
ment of specific APH inhibitors adapted from ePK or lipid kinase
inhibitor scaffolds that minimize cross-reactivity and undesired
side effects.
Modifying existing aminoglycosides
Many studies have been published on the modification of exist-
ing aminoglycosides to generate APH inhibitors that blocks
the aminoglycoside-binding pocket. These efforts, which include
aminoglycoside dimers, and aminoglycoside-small molecule con-
jugates, have been excellently reviewed elsewhere and will not be
recapitulated here (Houghton et al., 2010). A recent effort in this
direction deserves mentioning, however: Szychowski et al. have
developed a series of paromomycin analogs featuring hydropho-
bic substituents at the O2′′ position (5, Figure 6) (Szychowski
et al., 2011). These compounds have been shown to be active
against aminoglycoside sensitive strains but not their resistant
counterparts. Notably, they are not phosphorylated by APH(3′)-
IIIa and they act competitively with respect to the aminoglycoside
substrate and mixed uncompetitively with respect to ATP in
the inhibition of APH(3′)-IIIa and AAC(6′)-Ii. Unfortunately,
they do not demonstrate any synergistic effects with amikacin or
paromomycin against aminoglycoside-resistant strains.
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FIGURE 6 | Representative structures small molecule inhibitors. 1, CKI-7; 2, quercetin; 3, damnacanthal; 4, wortmannin; 5, paromomycin O2′′ -ether analog;
6, non-carbohydrate diamine inhibitor; 7, protein kinase C θ inhibitor.
In another study, Welch et al. used the 2-deoxystreptamine
core as a starting point to synthesize a series of non-carbohydrate
aminoglycoside analogs that extends to the phosphate-binding
site and thus show competitive inhibition toward ATP-binding
in several AMEs, including APH(3′)-IIIa and ANT(2′′)-Ia (6)
(Welch et al., 2005).
Uncompetitive inhibition
At this time, alternative inhibition mechanisms with small
molecules other than competitive inhibitors have not been exten-
sively explored in APH enzymes. However, known inhibitors of
kinases are by no means limited to small molecules that tar-
get the ATP-binding site. Recent pre-steady state kinetic studies
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on APH(3′)-IIIa have confirmed that ADP release is the rate-
limiting step in the reaction mechanism (Lallemand et al., 2012).
Theoretically, compounds that stabilize the enzyme-ADP com-
plex could serve as uncompetitive inhibitors and promise an
alternative route in the search of an effective APH inhibitor. In
another study, Boehr et al. probed cationic peptides for their
ability to inhibit aminoglycoside resistance enzymes on the basis
that functional studies have shown that APHs can phosphory-
late positively charged peptides. Several peptide candidates were
identified, including indolicidin, with potencies in the micro-
molar range (Boehr et al., 2003). Steady-state kinetic analyses
determined with APH(3′)-IIIa and APH(2′′)-Ia demonstrated
non-competitive inhibition patterns with respect to both the
nucleotide and the aminoglycoside substrate, which suggest that
the cationic peptides bind to APHs in a mode more complex
than simply competing with the aminoglycoside for its negatively
charged binding site. Although cationic peptides with antimicro-
bial properties remain an active field of investigation (Hancock
and Sahl, 2006; Pompilio et al., 2012), no further study has
been reported on their inhibitory effect on resistance enzymes.
Structural information detailing their mode of binding would
greatly advance our understanding of their mechanism of action
and preserve cationic peptides as a potential avenue for adjuvant
development.
OUTLOOK FOR APH INHIBITOR DEVELOPMENT
Although adapting ePK inhibitors presents a promising avenue
for the discovery of inhibitors of APHs, most if not all ePK
inhibitors were designed based on the scaffold for ATP-binding,
possibly limiting their adaptability to those APH enzymes that
utilize GTP as its phosphate source. Nonetheless, building on
the extensive efforts invested in the development of protein
kinase inhibitors over the past several decades, a structure-
guided approach of designing APH inhibitors could begin with
the ATP/GTP-binding templates of the hinge region. The gen-
eral purine-binding template consists of three groups capable of
forming hydrogen bonds with the ligand: the carbonyl group of
a residue in the N-terminus of the hinge [Ser91 in APH(3′)-
IIIa], and the amide nitrogen as well as the carbonyl group of
the residue two amino acids C-terminal to the first [Ala93 in
APH(3′)-IIIa] (Figure 5). Since all three groups form part of the
backbone, this template is conserved for all APHs despite poor
sequence similarity of the hinge region. However, it should be
noted that the relative orientation of the groups can vary for dif-
ferent APH enzymes depending on their nucleotide specificity,
since only a subset of two functional groups are involved in inter-
acting with either the adenine or guanine moiety. To complement
the purine-binding template, the inhibitor should contain a rel-
atively inflexible “head group” with at least one hydrogen-bond
donor and one acceptor that serves to anchor the molecule in
the purine-binding pocket. The inhibitor could then be extended
into the nucleoside pocket in two directions. The most appar-
ent space is that normally occupied by the ribose moiety. Many
ePK inhibitors, including CKI-7, take advantage of this pocket
and interact with residues on the catalytic loop C-terminal to
the catalytic aspartate [Ser194 in APH(3′)-IIIa]. Intriguingly,
space-filling models of multiple APHs with a bound ATP-analog
includingAPH(3′)-IIIa, APH(3′)-IIa, APH(2′′)-IVa, andAPH(9)-
Ia show a hydrophobic pocket toward the interior of the binding
cleft near atoms N7 and C8 of the adenine base (denoted by a
black arrow in Figure 5) that might be exploitable for increased
specificity and potency. In ePKs, this pocket is termed the back
pocket and its accessibility greatly depends on the bulk of the
gatekeeper residue (Zuccotto et al., 2010). Interestingly, the influ-
ence of the gatekeeper residue seems to be of reduced importance
in APH enzymes, where APH(2′′)-IIa (with Met85 as gatekeeper
residue) has virtually no accessible back pocket while APH(9)-
Ia (with Tyr100 as gatekeeper residue) has an extensive back
pocket due to the more open orientation of its N-terminal β-
sheet with respect to the binding cleft. The possibility of tar-
geting this hydrophobic cavity, coupled with the relatively low
sequence conservation and a high level of structural plasticity
in this region, offers valuable opportunities to obtain selectivity.
Finally, variations can be introduced to the intermediate portion
of the molecule linking the head group with the selectivity frag-
ment to optimize the pharmacokinetic properties of the small
molecule.
A similar approach to inhibitor development involving a head
group as anchor, an end group for selectivity, and a linker for
pharmacokinetics has been successfully applied to optimizing a
number of protein kinase inhibitors. Most recently, such efforts
have led to the discovery of a protein kinase C θ inhibitor with
strong in vivo potency in mice (7, Figure 6) (Jimenez et al.,
2013).
Despite the above, the growing body of structural knowl-
edge of different subfamilies of APH enzymes indicates that the
development of a universal APH inhibitor not recognized by
ePKs may not be achievable. In fact, the level of differences
among the APH subfamilies is on par with or greater than
those between APHs and their nearest ePK homologs. The diver-
sity in the active site architecture of APH proteins, evidenced
by the distinctive nucleotide and aminoglycoside substrate pro-
files for each individual member, suggests that pursuing selective
inhibitors for the different subfamilies rather than a broad-
spectrum inhibitor may bemore fruitful. Realistically, researching
specific inhibitors that target less widespread, atypical amino-
glycoside resistance enzymes which inactivate single drugs, such
as APH(9)-Ia or APH(4)-Ia, will unlikely prove profitable and
complications due to these enzymes may be more efficiently over-
come by developing modified aminoglycosides. However, in the
absence of a healthy pipeline for next-generation aminoglyco-
sides that circumvent resistance enzymes and given the ever-
growing spread of resistance to existing aminoglycosides due to
several key broad-spectrum enzymes, notably APH(3′)-IIIa and
AAC(6′)/APH(2′′), developing specific inhibitors that target the
ATP- and GTP-binding capabilities of these enzymes still present
invaluable steps of progress in the struggle against aminoglycoside
resistance.
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